Corrigendum to 'A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis' [International Journal of Gynecology and Obstetrics 108 (2010) 21-25]

The authors wish to clarify that analyses in the paper are based on the full-analysis set (FAS), excluding patients for whom data wereunavailable.FortherevisedAmericanFertilitySociety(rAFS)score,datawereunavailablein9.5%ofpatientsinthe2-mggroupgroupat24 weeks.The columns in Fig. 2 are adjusted to 100%, after excluding these missing data. Histologic examination at 24 weeks in the 2-mg and 4-mg groupsidentified endometriosis in 33.3% and 46.7%, and no endometriosis in 28.6% and 30.0% of women, with data unavailable in 38.1% and 23.3%,respectively.